More Videos
SPECIAL REPORT
MOST SHARED
- Tiger Woods Out of Hospital After Accident
- The Good Entrepreneur Winner
- Gold Will Collapse Like Oil Did in 2008: Charts
- Abu Dhabi Will Aid Debt-Fraught Dubai 'Case by Case'
- Halftime Report: Dubai - First Ripple Of Larger Crisis?
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Abu Dhabi Will Aid Debt-Fraught Dubai 'Case by Case'
- Banks With The Biggest Exposure to The UAE
- Dubai's Debt Woes Signal New Era for Creditors
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Tiger Woods Out of Hospital After Accident
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs.
The drugs are so pricey and may not be covered by insurance, so I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.
I called attention to the fact that U.S. sales of Pfizer's [PFE
Loading...
()
] Viagra went down sequentially. Analysts say that happened even with a nine percent Viagra price increase during the quarter. And BMO Capital Markets' Bert Hazlett says in a research note to clients this morning that Viagra prescriptions did indeed drop by four percent in Q2.
Yesterday, GlaxoSmithKline [GSK
Loading...
()
] reported sequentially flat sales of Levitra. But revenue from that impotence pill is so small ($26 million), it really doesn't register.
Then, this morning, Eli Lilly [LLY
Loading...
()
] announced that second quarter sales of Cialis in the U.S. went up only $5 million from the first quarter. And here, too, the company acknowledges that it raised the price. Deutsche Bank's Barbara Ryan says total worldwide prescriptions of Cialis are up six percent so far this year. So, maybe Cialis--because it lasts a day-and-a-half versus Levitra and Viagra which last a few hours or so--is simply taking more market share. Lilly also recently launched a one-a-day version of Cialis.
In a "First on CNBC" interview on "Squawk Box" this morning new LLY CEO John Lechleiter said, "I don't think we've got a good read on whether the economy is affecting Cialis sales or not." And he mentioned something interesting that I wasn't aware of: "It's the only product overseas that is not price restricted, so it's a product most people pay for out of their pocket."
But my case may be bolstered by a Dr. Benjamin Brewer who writes "The Doctor's Office" column for The Wall Street Journal. Yesterday, in a piece about the economy's impact on healthcare he offered this anecdote: "I'm getting fewer fill (prescription) requests for E.D. drugs, like Viagra, too."
Who knew that erectile dysfunction drug prescriptions might be an economic indicator? I will resist trying to coin a term for that.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes